Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection
NCT ID: NCT00810524
Last Updated: 2008-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
600 participants
INTERVENTIONAL
2007-01-31
2017-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
120 subjects (have family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is lower than 80u/L (early antiviral treatment).
lamivudine
100mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
Telbivudine
600mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
Enticavir
0.5mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2 years.
Adefovir Dipivoxil Tablets
10mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
B
120 subjects (have family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is higher than 80u/L (regular antiviral treatment).
lamivudine
100mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
Telbivudine
600mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
Enticavir
0.5mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2 years.
Adefovir Dipivoxil Tablets
10mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
C
180 subjects (have no family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is lower than 80u/L (early antiviral treatment).
lamivudine
100mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
Telbivudine
600mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
Enticavir
0.5mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2 years.
Adefovir Dipivoxil Tablets
10mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
D
180 subjects (have no family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is higher than 80u/L (regular antiviral treatment).
lamivudine
100mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
Telbivudine
600mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
Enticavir
0.5mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2 years.
Adefovir Dipivoxil Tablets
10mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
lamivudine
100mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
Telbivudine
600mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
Enticavir
0.5mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2 years.
Adefovir Dipivoxil Tablets
10mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HBeAg positive.
* HBV DNA over 10E5 copies/ml.
Exclusion Criteria
* Co infection of HIV, HCV, HEV, HAV, or HAV.
* Evidence of hepatic carcinoma.
* Evidence of autoimmune disease.
* Evidence of thyroid disease.
* History of mental sickness.
20 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sun Yat-sen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
The Third Affliated Hospital of Sun Yat-sen University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gao zhiliang, M. D.
Role: STUDY_DIRECTOR
Third Affiliated Hospital, Sun Yat-Sen University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Third Affiliated Hospital Of Sun Yat-sen University
Guangzhou, Guangdong, China
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Gao zhiliang, M. D.
Role: primary
Gao zhiliang, M. D.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SunYat-senU 5010 Hepatitis B
Identifier Type: -
Identifier Source: org_study_id